JAGSNPHARM

Jagsonpal Pharmaceuticals Share Price

₹589.25 +12.65 (2.19%)

21 Nov, 2024 14:16

SIP TrendupStart SIP in JAGSNPHARM

Start SIP

Performance

  • Low
  • ₹569
  • High
  • ₹606
  • 52 Week Low
  • ₹274
  • 52 Week High
  • ₹629
  • Open Price₹576
  • Previous Close₹577
  • Volume80,528

Investment Returns

  • Over 1 Month + 26.93%
  • Over 3 Month + 57.95%
  • Over 6 Month + 63.2%
  • Over 1 Year + 53.75%
SIP Lightning

Smart Investing Starts Here Start SIP with Jagsonpal Pharmaceuticals for Steady Growth!

Invest Now

Jagsonpal Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 64.3
  • PEG Ratio
  • -4.5
  • Market Cap Cr
  • 1,562
  • P/B Ratio
  • 8.3
  • Average True Range
  • 39.32
  • EPS
  • 10.1
  • Dividend Yield
  • 0.8
  • MACD Signal
  • 32.57
  • RSI
  • 60.68
  • MFI
  • 86

Jagsonpal Pharmaceuticals Financials

Jagsonpal Pharmaceuticals Technicals

EMA & SMA

Current Price
₹589.25
+ 12.65 (2.19%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹539.38
  • 50 Day
  • ₹487.85
  • 100 Day
  • ₹442.40
  • 200 Day
  • ₹406.18

Resistance and Support

588.48 Pivot Speed
  • R3 666.77
  • R2 644.63
  • R1 610.62
  • S1 554.47
  • S2 532.33
  • S3 498.32

What's your outlook on Jagsonpal Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jagsonpal Pharmaceuticals manufactures and markets pharmaceutical formulations, focusing on therapeutic areas like gynecology, orthopedics, and cardiovascular health. It serves both domestic and international markets, providing high-quality medicines to improve healthcare outcomes.

Jagsonpal Pharmaceuticals has an operating revenue of Rs. 226.85 Cr. on a trailing 12-month basis. An annual revenue de-growth of -10% needs improvement, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 22% and 55% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 27% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 78 which is a FAIR score but needs to improve its earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Jagsonpal Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-23 Quarterly Results & Stock Split
2024-08-07 Quarterly Results
2024-05-20 Audited Results & Final Dividend
2024-02-02 Quarterly Results
2023-11-03 Quarterly Results
Date Purpose Remarks
2024-09-06 FINAL Rs.5.00 per share(100%)Final Dividend
2023-08-21 FINAL Rs.5.00 per share(100%)Dividend
2021-11-01 INTERIM Rs.4.00 per share(80%)Interim Dividend

Jagsonpal Pharmaceuticals F&O

Jagsonpal Pharmaceuticals Shareholding Pattern

67.97%
0.11%
2.3%
0%
20.38%
9.24%

About Jagsonpal Pharmaceuticals

  • NSE Symbol
  • JAGSNPHARM
  • BSE Symbol
  • 507789
  • Managing Director
  • Mr. Manish Gupta
  • ISIN
  • INE048B01027

Similar Stocks to Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals FAQs

Jagsonpal Pharmaceuticals share price is ₹589 As on 21 November, 2024 | 14:02

The Market Cap of Jagsonpal Pharmaceuticals is ₹1562.4 Cr As on 21 November, 2024 | 14:02

The P/E ratio of Jagsonpal Pharmaceuticals is 64.3 As on 21 November, 2024 | 14:02

The PB ratio of Jagsonpal Pharmaceuticals is 8.3 As on 21 November, 2024 | 14:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23